Gateway Health Alliances, Inc.

United States of America

Back to Profile

1-42 of 42 for Gateway Health Alliances, Inc. Sort by
Query
Aggregations
IP Type
        Patent 23
        Trademark 19
Jurisdiction
        United States 30
        Europe 8
        World 4
Date
2024 10
2020 1
Before 2020 31
IPC Class
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines 9
A61K 36/185 - Magnoliopsida (dicotyledons) 9
A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae 8
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof 5
A61K 31/015 - Hydrocarbons carbocyclic 4
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 19
01 - Chemical and biological materials for industrial, scientific and agricultural use 1
Status
Pending 5
Registered / In Force 37

1.

Q.Actin

      
Application Number 019103172
Status Registered
Filing Date 2024-11-08
Registration Date 2025-03-28
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

2.

DYG-400

      
Application Number 019103173
Status Registered
Filing Date 2024-11-08
Registration Date 2025-03-28
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

3.

Resargin

      
Application Number 019103224
Status Pending
Filing Date 2024-11-08
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

4.

IGOB131

      
Application Number 019103240
Status Pending
Filing Date 2024-11-08
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

5.

Dyglomera

      
Application Number 019103258
Status Registered
Filing Date 2024-11-08
Registration Date 2025-03-28
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

6.

CQR-300

      
Application Number 019103259
Status Pending
Filing Date 2024-11-08
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

7.

Somnoril

      
Application Number 019103220
Status Registered
Filing Date 2024-11-08
Registration Date 2025-03-28
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

8.

Dyglofit

      
Application Number 019103239
Status Registered
Filing Date 2024-11-08
Registration Date 2025-03-27
Owner Gateway Health Alliances, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements.

9.

SOMNORIL

      
Serial Number 98600839
Status Pending
Filing Date 2024-06-14
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements

10.

SOMNORIL

      
Serial Number 98601881
Status Pending
Filing Date 2024-06-14
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dichrostachys glomerata sold as a component ingredient of dietary and nutritional supplements

11.

Methods and related compositions for reducing oxidative stress

      
Application Number 16426214
Grant Number 10905731
Status In Force
Filing Date 2019-05-30
First Publication Date 2020-12-03
Grant Date 2021-02-02
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Baillonella toxisperma provide antioxidant and neuroprotective benefits and prevent oxidative stress in mammals.

IPC Classes  ?

  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K 36/185 - Magnoliopsida (dicotyledons)

12.

Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma

      
Application Number 15965406
Grant Number 10632090
Status In Force
Filing Date 2018-04-27
First Publication Date 2018-08-30
Grant Date 2020-04-28
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor
  • Kothari, Shil
  • Troxel, Gary

Abstract

Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.

IPC Classes  ?

  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/05 - Phenols
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

13.

Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma

      
Application Number 14924715
Grant Number 09844526
Status In Force
Filing Date 2015-10-28
First Publication Date 2017-05-04
Grant Date 2017-12-19
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor
  • Kothari, Shil
  • Troxel, Gary

Abstract

Methods of increasing the plasma concentration of resveratrol in a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.

IPC Classes  ?

  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/05 - Phenols

14.

Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma

      
Application Number 14924717
Grant Number 09782375
Status In Force
Filing Date 2015-10-28
First Publication Date 2017-05-04
Grant Date 2017-10-10
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor
  • Kothari, Shil
  • Troxel, Gary

Abstract

Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.

IPC Classes  ?

  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/05 - Phenols

15.

DYG-400

      
Serial Number 86799949
Status Registered
Filing Date 2015-10-26
Registration Date 2018-03-20
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Plant extract sold in bulk as a dietary and nutritional supplement

16.

Methods and compositions to reduce fat gain, promote weight loss in animals

      
Application Number 14715487
Grant Number 10279003
Status In Force
Filing Date 2015-05-18
First Publication Date 2015-09-10
Grant Date 2019-05-07
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina

17.

DYGLOFIT

      
Serial Number 86691452
Status Registered
Filing Date 2015-07-13
Registration Date 2017-10-31
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Spice extract sold as a component of dietary and nutritional supplements

18.

Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, and leptin levels and increasing adiponectin levels

      
Application Number 14242742
Grant Number 09427453
Status In Force
Filing Date 2014-04-01
First Publication Date 2014-07-31
Grant Date 2016-08-30
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Irvingia gabonensis.

IPC Classes  ?

  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K 36/185 - Magnoliopsida (dicotyledons)

19.

Methods and compositions to reduce fat gain, promote weight loss in mammals

      
Application Number 14242775
Grant Number 10279001
Status In Force
Filing Date 2014-04-01
First Publication Date 2014-07-31
Grant Date 2019-05-07
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.

IPC Classes  ?

  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina

20.

Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, and leptin levels and increasing adiponectin levels

      
Application Number 14242749
Grant Number 09480724
Status In Force
Filing Date 2014-04-01
First Publication Date 2014-07-31
Grant Date 2016-11-01
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Irvingia gabonensis.

IPC Classes  ?

  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K 36/185 - Magnoliopsida (dicotyledons)

21.

Methods and compositions to reduce fat gain, promote weight loss in mammals

      
Application Number 14242794
Grant Number 10279002
Status In Force
Filing Date 2014-04-01
First Publication Date 2014-07-31
Grant Date 2019-05-07
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina

22.

Methods and compositions to reduce fat gain, promote weight loss in mammals

      
Application Number 14242800
Grant Number 09775873
Status In Force
Filing Date 2014-04-01
First Publication Date 2014-07-17
Grant Date 2017-10-03
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/185 - Magnoliopsida (dicotyledons)
  • A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina

23.

LIPOFUEL

      
Serial Number 86106119
Status Registered
Filing Date 2013-10-30
Registration Date 2016-08-02
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements

24.

Dichrostachys glomerata on various cardiovascular risk factors and metabolic syndrome

      
Application Number 13568708
Grant Number 08623432
Status In Force
Filing Date 2012-08-07
First Publication Date 2012-11-29
Grant Date 2014-01-07
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Dichrostachys glomerata, to the mammal, whereby the administering of the composition to the mammal is effective in reducing bodyweight in the mammal.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

25.

Xylopia aethiopica on various cardiovascular risk factors and metabolic syndrome

      
Application Number 13557056
Grant Number 08394432
Status In Force
Filing Date 2012-07-24
First Publication Date 2012-11-15
Grant Date 2013-03-12
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Xylopia aethiopica, to the mammal, whereby the administering of the composition to the mammal is effective in reducing bodyweight in the mammal.

IPC Classes  ?

  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

26.

Hypodaphnis zenkeri on various cardiovascular risk factors and metabolic syndrome

      
Application Number 13557000
Grant Number 08361523
Status In Force
Filing Date 2012-07-24
First Publication Date 2012-11-15
Grant Date 2013-01-29
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyoug

Abstract

Hypodaphnis zenkeri, to an overweight subject, whereby the administering of the composition to the overweight subject is effective in reducing bodyweight in the overweight subject.

IPC Classes  ?

  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

27.

IGOB-131

      
Serial Number 85423839
Status Registered
Filing Date 2011-09-15
Registration Date 2012-12-11
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Irvingia gabonesis plant used as an ingredient in dietary and nutritional supplements

28.

Xylopia aethiopica XA on various cardiovascular risk factors and metabolic syndrome

      
Application Number 12901480
Grant Number 08241682
Status In Force
Filing Date 2010-10-08
First Publication Date 2011-05-12
Grant Date 2012-08-14
Owner Gateway Health Alliances, Inc. (USA)
Inventor Oben, Julius E.

Abstract

Dichrostachys glomerata, to a mammal, whereby the administering of the composition to the mammal is effective in reducing LDL cholesterol levels in the mammal.

IPC Classes  ?

  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
  • A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae

29.

Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals

      
Application Number 12686014
Grant Number 08394860
Status In Force
Filing Date 2010-01-12
First Publication Date 2010-05-06
Grant Date 2013-03-12
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyong

Abstract

C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, α-amylase and α-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-O-rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-O″-acetate and parthenocissin A.

IPC Classes  ?

  • A01N 31/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
  • A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • C09B 31/00 - Disazo or polyazo dyes of the type A → B → C, A → B → C → D, or the like, prepared by diazotising and coupling
  • C09B 33/00 - Disazo or polyazo dyes of the types A → K ← B, A → B → K ← C, or the like, prepared by diazotising and coupling
  • C09B 35/00 - Disazo or polyazo dyes of the type A ← D → B prepared by diazotising and coupling
  • C09B 37/00 - Azo dyes prepared by coupling the diazotised amine with itself

30.

Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals

      
Application Number 12685990
Grant Number 08362090
Status In Force
Filing Date 2010-01-12
First Publication Date 2010-05-06
Grant Date 2013-01-29
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyong

Abstract

C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, α-amylase and α-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-O-rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-O″-acetate and parthenocissin A.

IPC Classes  ?

  • A01N 31/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
  • A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • C09B 31/00 - Disazo or polyazo dyes of the type A → B → C, A → B → C → D, or the like, prepared by diazotising and coupling
  • C09B 33/00 - Disazo or polyazo dyes of the types A → K ← B, A → B → K ← C, or the like, prepared by diazotising and coupling
  • C09B 35/00 - Disazo or polyazo dyes of the type A ← D → B prepared by diazotising and coupling
  • C09B 37/00 - Azo dyes prepared by coupling the diazotised amine with itself

31.

METHODS AND COMPOSITIONS USING IRVINGIA GABONENSIS TO REDUCE WEIGHT, CONTROL OBESITY, EFFECT ADIPOGENESIS, LOWER PPAR-GAMMA, LEPTIN, G3PDH AND TRIGLYC-ERIDES LEVELS AND INCREASE ADIPONECTIN LEVELS

      
Application Number US2009061102
Publication Number 2010/045621
Status In Force
Filing Date 2009-10-16
Publication Date 2010-04-22
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius, E.

Abstract

In one embodiment, a method is provided for lowering PPAR-Gamma in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce PPAR-Gamma levels in the mammal. In other embodiments, among other things, methods are provided for reducing triglyceride levels, inhibiting or reducing G3PDH activity, reducing body weight and increasing adiponectin levels in a mammal by administering Irvingia gabonensis.

IPC Classes  ?

32.

IRVINGIA GABONENSIS TO TREAT AND PREVENT METABOLIC SYNDROME AND REDUCE TOTAL CHOLESTEROL, LDL CHOLESTEROL, BLOOD GLUCOSE, C-REACTIVE PROTEIN, AND LEPTIN LEVELS AND INCREASING INCREASING ADIPONECTIN LEVELS

      
Application Number US2009061105
Publication Number 2010/045623
Status In Force
Filing Date 2009-10-16
Publication Date 2010-04-22
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius, E.

Abstract

In one embodiment, a method is provided for lowering C-reactive protein levels in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce C-reactive protein levels in the mammal. Other embodiments include, among other things, lowering leptin levels, increasing adiponectin levels, reducing body weight, decreasing LDL and total cholesterol levels, increasing fat loss, and reducing waist size in a mammal using administering a composition containing an effective amount of Irvingia gabonensis.

IPC Classes  ?

33.

Plant extract mixtures and their uses

      
Application Number 12504327
Grant Number 08318213
Status In Force
Filing Date 2009-07-16
First Publication Date 2009-12-31
Grant Date 2012-11-27
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyong

Abstract

Cissus quadrangularis to reduce fat and cause weight loss in a mammal. Such compositions have beneficial activity principally in controlling weight gain and obesity.

IPC Classes  ?

  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof

34.

DYGLOMERA

      
Serial Number 77781616
Status Registered
Filing Date 2009-07-15
Registration Date 2013-04-30
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements

35.

IGOB131

      
Serial Number 77715799
Status Registered
Filing Date 2009-04-16
Registration Date 2011-03-15
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Plant extract sold in bulk as a dietary and nutritional supplement

36.

CQR-300

      
Serial Number 77715802
Status Registered
Filing Date 2009-04-16
Registration Date 2012-10-02
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements

37.

METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE. α-AMYLASE AND α-GLUCOSIDASE ACTIVITY IN MAMMALS

      
Application Number US2008075739
Publication Number 2009/035987
Status In Force
Filing Date 2008-09-09
Publication Date 2009-03-19
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius, Enyong

Abstract

The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, α-amylase and α-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-0- rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5- dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-0'-acetate and parthenocissin A.

IPC Classes  ?

  • A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid

38.

Methods and related compositions using specific indanes to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals

      
Application Number 11855084
Grant Number 07659313
Status In Force
Filing Date 2007-09-13
First Publication Date 2009-03-19
Grant Date 2010-02-09
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius Enyong

Abstract

C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition and related methods for reducing body weight and/or inhibiting any combination of lipase, α-amylase and α-glucosidase is provided. The composition contains an effective amount of one or more flavonoids or indanes selected from 3-O-rhamnopyranosylkaempferol, 3-(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-hydroxyphenyl)indane-4,6-diol, quercitrin, rhamnitrin, rhamnocitrin, quercitrin-3-O″-acetate and parthenocissin A.

IPC Classes  ?

  • A01N 31/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • C09B 29/00 - Monoazo dyes prepared by diazotising and coupling
  • C09B 31/00 - Disazo or polyazo dyes of the type A → B → C, A → B → C → D, or the like, prepared by diazotising and coupling
  • C09B 33/00 - Disazo or polyazo dyes of the types A → K ← B, A → B → K ← C, or the like, prepared by diazotising and coupling
  • C09B 35/00 - Disazo or polyazo dyes of the type A ← D → B prepared by diazotising and coupling
  • C09B 37/00 - Azo dyes prepared by coupling the diazotised amine with itself

39.

FAT 2 FUEL

      
Serial Number 77573689
Status Registered
Filing Date 2008-09-18
Registration Date 2012-07-31
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Dietary and nutritional supplements

40.

METHODS AND COMPOSITIONS FOR IMPROVING CARDIOVASCULAR RISK FACTORS AND METABOLIC RISK FACTORS THAT CAUSE SYNDROME X

      
Application Number US2007062592
Publication Number 2007/101066
Status In Force
Filing Date 2007-02-22
Publication Date 2007-09-07
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Kothari, Shil, C.

Abstract

The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300mg Cissus quadrangularis plant extract provided to obese humans daily for six weeks was effective to provide numerous health benefits including weight loss, improving the bodies fat burning mechanisms, increasing serum serotonin levels which causes appetite suppression and prevents binge eating and/or emotional eating, reducing total cholesterol, LDL cholesterol, triglyceride levels, fasting blood sugar levels and blood pressure, and increasing HDL or 'good' cholesterol levels. Additional university controlled experiments also showed that extracts from the Cissus quadrangularis plant were effective in increasing lipase inhibition, α-amylase inhibition, α-glucosidase inhibition in rodents and that large doses of Cissus quadrangularis plant extracts were not toxic to rodents.

IPC Classes  ?

  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

41.

LEPTICORE

      
Serial Number 77209126
Status Registered
Filing Date 2007-06-18
Registration Date 2008-10-07
Owner Gateway Health Alliances, Inc. ()
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Chemical additives for use in the manufacture of nutritional supplements, pharmaceuticals, food, and drinks Dietary and nutritional supplements; Nutritional additives for use in foods and dietary supplements for human consumption

42.

Method and composition for reducing body weight and improving control of body lipids

      
Application Number 11557916
Grant Number 07537790
Status In Force
Filing Date 2006-11-08
First Publication Date 2007-03-22
Grant Date 2009-05-26
Owner GATEWAY HEALTH ALLIANCES, INC. (USA)
Inventor Oben, Julius

Abstract

Methods and composition using plants from the Irvingiaceae family to reduce or prevent one or more symptoms of Syndrome X in a mammal and provide numerous other health related benefits. Methods and compositions using the Irvinga gabonensis plant to reduce lipid levels, BMI and body weight, blood pressure, triglyceride levels, total amount of stored in the body, cholesterol levels, salivary and pancreatic alpha-amylase activity and pancreatic lipase activity, LDL cholesterol, to increase HDL cholesterol, to control blood glucose and to prevent or reduce the effects of insulin resistance, diabetes, and heart disease.

IPC Classes  ?

  • A01K 65/00 - Fish stringers
  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines